A past study showed that people with type 2 diabetes and heart disease or high blood pressure male 5-year incidence of ED than those without type 2 diabetes and heart disease and hypertension in men, but the incidence of ED increases with age. Currently in Shanghai, Beijing, Guangzhou and other big cities diabetes prevalence rate has reached about 8%. According to International Diabetes Federation (IDF) estimates that there will be emerging in China each year 1.01 million patients with diabetes, to 2025, China will have 59.3 million diabetics.
A study in 2003 showed that more than 50% of diabetic patients will occur in the next 10 years, ED. Microangiopathy of diabetes can occur in almost all parts of the body, such as diabetic nephropathy, diabetic retinopathy, diabetic neuropathy and diabetic cardiomyopathy and so on. For men, diabetic patients, ED is the occurrence of a result of these microvascular disease. Therefore, ED as an early indication of men with diabetes, one of the unique.
A past study showed that people with type 2 diabetes and heart disease or high blood pressure male 5-year incidence of ED than those without type 2 diabetes and heart disease and hypertension in men, but the incidence of ED increases with age. Cologne, Germany, in 2000 a survey showed that 40 to 59 years old, diabetic patients and non-diabetic ED are the most significant difference in the incidence (P <0.0001). Another study, ED patients with diabetes a sensitive clinical manifestations, in the ED were men, 13% and 17% of patients and newly diagnosed diabetes.
With IIEF-EF score of measure, erectile function was abnormal: 22 ~ 25 minutes; mild to moderate abnormalities: 17 ~ 21 minutes; moderate Exception: 11 ~ 16 minutes; severely abnormal: "11 points. In 2003 a study showed that diabetic patients with ED on vardenafil in patients with treatment of 12 weeks, vardenafil 10 mg group and 20 mg groups compared with the placebo group the final IIEF-EF score increased significantly (17.1 points, 19.0 points for 12.6 points, P <0.0001). In the 12-week course of treatment, each patient's penis insertion success rate (SEP2) in the vardenafil 10 mg group, 61%, 20 mg group was 64%, while the placebo group was only 36% (P <0.0001 ); each case the success rate of patients with sexual intercourse (SEP3) in the 10 mg group, 49%, 20 mg group, 54%, placebo group was only 23% (P <0.0001); general assessment questionnaire (GAQ) showed that Vardenafil 20 mg, 10 mg and placebo groups in patients with erectile function improvement in the proportion of 72%, 57% and 13%, two-dose treatment group were significantly higher than the placebo group (P <0.0001) (Figure 2 ). The results show that vardenafil can improve diabetic patients with ED success rate of insertion of the penis, sexual intercourse success rate and an overall improvement in the rate of sexual life.
Past studies have shown, regardless of the level of HbA1c in patients with diabetes mellitus, vardenafil may alleviate the symptoms of ED, indicating vardenafil on erectile function improvement in the situation has nothing to do with blood sugar control.
Vardenafil Security
Type 6 Phosphodiesterase (PDE6) mainly in the retina, if the high selectivity for PDE6 will harm the retina, especially for patients with diabetes is more dangerous. Vardenafil is a highly selective type 5 phosphodiesterase (PDE5) inhibitors, the selectivity of PDE6 is low, security, better, but also more suitable for diabetic patients with ED. Vardenafil, Sildenafil and Tadalafil half the amount of potent inhibitor (IC50) Do as 0.7 nM, 6.6 nM and 9.4 nM, shows vardenafil on PDE5 inhibition effect of the strongest adverse reactions occurred the possibility of minimal.
Vardenafil Common adverse reactions include facial flushing, headache, stuffy nose, or rhinitis. In addition, studies have confirmed that vardenafil good cardiovascular safety, myocardial infarction and cardiac death rates were 0.4% and 0.05%, lower than sildenafil (0.8% and 0.23%) and tadalafil (1.2% and 0.3%).
